AgeIndex: A Whole-Genome Epigenetic Aging and Rejuvenation Index

Researchers at Stanford have developed AgeIndex, the first whole-genome epigenetic aging index and method based on Whole Genome Bisulfite Sequencing (WGBS) assays. AgeIndex provides an unbiased estimate of the biological age of any cell in the body (human or other mammal) by measuring the loss of its epigenetic information. As cells replicate, the transfer of epigenetic information to cells is not completely faithful, therefore, cellular replication accompanies a gradual loss of important information. Using a large dataset of WGBS data, the researchers demonstrated that the age-dependent loss of epigenetic information could be measured by comparing the cell with embryonic stem cells (defined as Age 0 cells). AgeIndex is capable of quantifying biological aging, at a cellular and chromosomal level, in different tissues, both in vitro and in vivo, and therefore able to assess the efficacy of new anti- aging and rejuvenation treatments. While several epigenetic aging 'clocks' have been developed recently they are not tuned for rejuvenation. A robust measure to accurately quantify aging as well as rejuvenation has yet to be commercialized.

Stage of Development
The researchers have tested AgeIndex in human and mice using 4 different sequencing and microarray assays (WGBS, RRBS, EPIC, and Methyl 450K assays). To their knowledge, this is the only aging index that successfully works with any tested assays. Optimization efforts are ongoing.